Venus Remedies has surged 6.3% to Rs 291 after the company said it has received patent from Mexico for its novel antibiotic product Potentox.
Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, Venus Remedies said in a statement.
The patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.
The stock opened at Rs 279 and touched high of Rs 299 on BSE. A combined around 175,000 shares have changed hands on the counter so far on BSE and NSE.
Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, Venus Remedies said in a statement.
The patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.
The stock opened at Rs 279 and touched high of Rs 299 on BSE. A combined around 175,000 shares have changed hands on the counter so far on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%